Bifogade filer
Kurs
+3,66%
Likviditet
0,94 MSEK
Kalender
Est. tid* | ||
2025-11-21 | 08:30 | Kvartalsrapport 2025-Q3 |
2025-08-29 | 08:30 | Kvartalsrapport 2025-Q2 |
2025-05-28 | 08:30 | Kvartalsrapport 2025-Q1 |
2025-05-19 | N/A | X-dag ordinarie utdelning ISAB 0.00 SEK |
2025-05-16 | N/A | Årsstämma |
2025-02-28 | - | Bokslutskommuniké 2024 |
2024-11-20 | - | Kvartalsrapport 2024-Q3 |
2024-09-04 | - | Extra Bolagsstämma 2024 |
2024-08-28 | - | Kvartalsrapport 2024-Q2 |
2024-05-28 | - | Kvartalsrapport 2024-Q1 |
2024-05-15 | - | X-dag ordinarie utdelning ISAB 0.00 SEK |
2024-05-14 | - | Årsstämma |
2024-02-28 | - | Bokslutskommuniké 2023 |
2023-11-22 | - | Kvartalsrapport 2023-Q3 |
2023-08-29 | - | Kvartalsrapport 2023-Q2 |
2023-05-31 | - | Kvartalsrapport 2023-Q1 |
2023-05-15 | - | X-dag ordinarie utdelning ISAB 0.00 SEK |
2023-05-12 | - | Årsstämma |
2023-02-28 | - | Bokslutskommuniké 2022 |
2022-11-22 | - | Kvartalsrapport 2022-Q3 |
2022-08-29 | - | Kvartalsrapport 2022-Q2 |
2022-06-08 | - | X-dag ordinarie utdelning ISAB 0.00 SEK |
2022-05-23 | - | Kvartalsrapport 2022-Q1 |
2022-05-06 | - | Årsstämma |
2022-02-28 | - | Bokslutskommuniké 2021 |
2021-11-24 | - | Kvartalsrapport 2021-Q3 |
2021-08-26 | - | Kvartalsrapport 2021-Q2 |
2021-06-22 | - | Extra Bolagsstämma 2021 |
2021-06-09 | - | X-dag ordinarie utdelning ISAB 0.00 SEK |
2021-06-08 | - | Årsstämma |
2021-05-19 | - | Kvartalsrapport 2021-Q1 |
2021-02-25 | - | Bokslutskommuniké 2020 |
2020-11-26 | - | Kvartalsrapport 2020-Q3 |
2020-08-26 | - | Kvartalsrapport 2020-Q2 |
2020-06-12 | - | Extra Bolagsstämma 2020 |
2020-05-13 | - | X-dag ordinarie utdelning ISAB 0.00 SEK |
2020-05-12 | - | Årsstämma |
2020-05-07 | - | Kvartalsrapport 2020-Q1 |
2020-02-20 | - | Bokslutskommuniké 2019 |
2019-11-14 | - | Kvartalsrapport 2019-Q3 |
2019-08-22 | - | Kvartalsrapport 2019-Q2 |
2019-05-22 | - | Årsstämma |
2019-05-16 | - | Kvartalsrapport 2019-Q1 |
2019-05-10 | - | X-dag ordinarie utdelning ISAB 0.00 SEK |
2019-02-21 | - | Bokslutskommuniké 2018 |
2018-12-13 | - | Extra Bolagsstämma 2018 |
2018-11-15 | - | Kvartalsrapport 2018-Q3 |
2018-08-22 | - | Kvartalsrapport 2018-Q2 |
2018-05-24 | - | X-dag ordinarie utdelning ISAB 0.00 SEK |
2018-05-23 | - | Årsstämma |
2018-05-16 | - | Kvartalsrapport 2018-Q1 |
2018-02-22 | - | Bokslutskommuniké 2017 |
2017-11-17 | - | Kvartalsrapport 2017-Q3 |
2017-08-28 | - | Kvartalsrapport 2017-Q2 |
Beskrivning
Land | Sverige |
---|---|
Lista | Spotlight |
Sektor | Hälsovård |
Industri | Medicinteknik |
(Stockholm, 19 November 2021) The Institute of Environmental Medicine (IMM) at Karolinska Institutet has extended its lease of ISAB's aerosol generation platform PreciseInhale[ ][®]. The extended lease lasts for the first half of 2022 and includes ISAB's innovative new in vivo module for aerosol exposures to guinea pigs. IMM is one of the world's most innovative pulmonary research bodies, and a returning ISAB customer. The original agreement was signed and announced in March 2020.
The extended lease includes ISAB's new in vivo module for aerosol exposures to guinea pigs. Guinea pigs are a highly relevant test subjects for inhalation studies. Human and guinea pigs share many similarities in lung anatomy, physiology, pharmacology, particularly airway autonomic control and response to allergens.
The new module employs ISAB's unique one-animal-at-a-time precision dosing method - with single animals being gently dosed through a controlled exposure, generating high-precision data and reducing the need for large numbers of test animals. The guinea pig module is attracting interest from several other customers.
The extended lease is between ISAB and IMM Associate Professor Mikael Adner, Head of the Unit for Experimental Asthma and Allergy Research, a leading expert in pulmonary research and the author of over 100 peer-reviewed papers. Assoc Professor Adner: "We have recently developed a unique guinea pig asthma model where we use relevant allergens and exposure through the airways. With the PreciseInhale[®] we will be able to deliver aerosol with even lung distribution that also reaches the peripheral parts. This will be an important tool in our asthma research. "
ISAB CEO Manoush Masarrat: "Karolinska Institutet is a much-valued, long-term customer and we are pleased to continue our agreement with them. The fact that customers of this calibre keep returning speaks clearly to the exceptional value and precision of our tools."
Manoush Masarrat, CEO
E-mail: Manoush.masarrat@inhalation.se
Mobile: +46 (0)73 628 9153